PMID- 22871042
OWN - NLM
STAT- MEDLINE
DCOM- 20130328
LR  - 20181202
IS  - 1744-7607 (Electronic)
IS  - 1742-5255 (Linking)
VI  - 8
IP  - 11
DP  - 2012 Nov
TI  - Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder 
      treatment in females.
PG  - 1387-408
LID - 10.1517/17425255.2012.714365 [doi]
AB  - INTRODUCTION: Antimuscarinics (AMs) are the mainstay of pharmacological treatment 
      of overactive bladder (OAB), a symptom complex defined by the presence of urinary 
      urgency, usually associated with frequency and nocturia, with or without urgency 
      urinary incontinence. The AMs used to treat OAB differ in their pharmacological 
      profiles, which may affect their potential for causing adverse effects (AEs). 
      AREAS COVERED: The present article aims to review the literature about 
      pharmacokinetics (PK) of the different AMs used in the treatment of OAB. 
      Furthermore, the AEs related to the use of these drugs and their incidence are 
      presented. This systematic review is based on material searched and obtained via 
      Medline, Pubmed and EMBASE up to March 2012 using the search terms "adverse 
      events, pharmacokinetics, tolerability" in combination with "darifenacin, 
      fesoterodine, imidafenacin, oxybutynin, propiverine, solifenacin, tolterodine, 
      and trospium." EXPERT OPINION: Antimuscarinics are the first-line pharmacological 
      treatment for OAB. Despite the development of new molecules that improve their 
      efficacy/safety profile, there are some drugs that are pharmacokinetically more 
      appropriate to be prescribed in specific populations such as patients with 
      neurological disease or the elderly. Moreover, research should be encouraged in 
      evaluating antimuscarinics in conjunction with other drugs such as estrogens or 
      beta-agonists. The identification of prognostic criteria for pharmacological 
      therapy would be helpful.
FAU - Leone Roberti Maggiore, Umberto
AU  - Leone Roberti Maggiore U
AD  - University of Genoa, San Martino Hospital and National Institute for Cancer 
      Research, Department of Obstetrics and Gynaecology, Genoa, Italy.
FAU - Salvatore, Stefano
AU  - Salvatore S
FAU - Alessandri, Franco
AU  - Alessandri F
FAU - Remorgida, Valentino
AU  - Remorgida V
FAU - Origoni, Massimo
AU  - Origoni M
FAU - Candiani, Massimo
AU  - Candiani M
FAU - Venturini, Pier Luigi
AU  - Venturini PL
FAU - Ferrero, Simone
AU  - Ferrero S
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20120808
PL  - England
TA  - Expert Opin Drug Metab Toxicol
JT  - Expert opinion on drug metabolism & toxicology
JID - 101228422
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Benzilates)
RN  - 0 (Benzofurans)
RN  - 0 (Cresols)
RN  - 0 (Drug Combinations)
RN  - 0 (Imidazoles)
RN  - 0 (Mandelic Acids)
RN  - 0 (Muscarinic Antagonists)
RN  - 0 (Pyrrolidines)
RN  - 0 (Quinuclidines)
RN  - 0 (Tetrahydroisoquinolines)
RN  - 33RU150WUN (Phenylpropanolamine)
RN  - 468GE2241L (propiverine)
RN  - 5T619TQR3R (Tolterodine Tartrate)
RN  - 621G617227 (fesoterodine)
RN  - APG9819VLM (darifenacin)
RN  - K9P6MC7092 (oxybutynin)
RN  - KKA5DLD701 (Solifenacin Succinate)
RN  - XJR8Y07LJO (imidafenacin)
SB  - IM
MH  - Benzhydryl Compounds/therapeutic use
MH  - Benzilates/therapeutic use
MH  - Benzofurans/therapeutic use
MH  - Chronic Disease
MH  - Cresols/therapeutic use
MH  - Drug Combinations
MH  - Female
MH  - Humans
MH  - Imidazoles/therapeutic use
MH  - Mandelic Acids/therapeutic use
MH  - Muscarinic Antagonists/*adverse effects/*pharmacokinetics
MH  - Nocturia/complications/drug therapy
MH  - Phenylpropanolamine/therapeutic use
MH  - Pyrrolidines/therapeutic use
MH  - Quinuclidines/therapeutic use
MH  - Solifenacin Succinate
MH  - Tetrahydroisoquinolines/therapeutic use
MH  - Tolterodine Tartrate
MH  - Urinary Bladder, Overactive/complications/*drug therapy
MH  - Urinary Incontinence/complications/drug therapy
EDAT- 2012/08/09 06:00
MHDA- 2013/03/30 06:00
CRDT- 2012/08/09 06:00
PHST- 2012/08/09 06:00 [entrez]
PHST- 2012/08/09 06:00 [pubmed]
PHST- 2013/03/30 06:00 [medline]
AID - 10.1517/17425255.2012.714365 [doi]
PST - ppublish
SO  - Expert Opin Drug Metab Toxicol. 2012 Nov;8(11):1387-408. doi: 
      10.1517/17425255.2012.714365. Epub 2012 Aug 8.